-
Effect of patient navigation with or without financial incentives on viral suppression among hospitalized patients with HIV infection and substance use: A randomized trial.
Metsch LR, Feaster DJ, Gooden LK, Matheson T, Stitzer ML, Das M, Jain MK, Rodriguez AE, Armstrong WS, Lucas GM, Nijhawan AE, Drainoni M, Herrera P, Vergara-Rodriguez P, Jacobson JM, Mugavero MJ, Sullivan M, Daar ES, McMahon DK, Ferris DC, Lindblad R, VanVeldhuisen PC, Oden NL, Castellon PC, Tross S, Haynes LF, Douaihy AB, Sorensen JL, Metzger DS, Mandler RN, Colfax GN, del Rio C. Effect of patient navigation with or without financial incentives on viral suppression among hospitalized patients with HIV infection and substance use: A randomized trial. JAMA 2016;316(2):156-170.
-
Design of the NIDA Clinical Trials Network validation study of Tobacco, Alcohol, Prescription Medications, and Substance Use/Misuse (TAPS) Tool.
Wu L, McNeely J, Subramaniam GA, Sharma G, VanVeldhuisen PC, Schwartz RP. Design of the NIDA Clinical Trials Network validation study of Tobacco, Alcohol, Prescription Medications, and Substance Use/Misuse (TAPS) Tool. Contemporary Clinical Trials 2016;50:90-97.
-
Examining the efficacy of HIV risk-reduction counseling on the sexual risk behaviors of a national sample of drug abuse treatment clients: Analysis of subgroups.
Gooden LK, Metsch LR, Pereyra MR, Malotte CK, Haynes LF, Douaihy AB, Chally J, Mandler RN, Feaster DJ. Examining the efficacy of HIV risk-reduction counseling on the sexual risk behaviors of a national sample of drug abuse treatment clients: Analysis of subgroups. AIDS and Behavior 2016;20(9):1893-1906.
-
Hair analysis and its concordance with self-report for drug users presenting in emergency departments.
Sharma G, Oden NL, VanVeldhuisen PC, Bogenschultz MP. Hair analysis and its concordance with self-report for drug users presenting in emergency departments. Drug and Alcohol Dependence 2016;167:149-155.
-
NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.
Lee JD, Nunes EV, Novo P, Bailey GL, Brigham GS, Cohen AJ, Fishman MJ, Ling W, Lindblad R, Shmueli-Blumberg D, Stablein D, May J, Salazar D, Liu DS, Rotrosen J. NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale. Contemporary Clinical Trials 2016;50:253-264.
-
Mortality rates among substance use disorder participants in clinical trials: Pooled analysis of twenty-two clinical trials within the National Drug Abuse Treatment Clinical Trials Network.
Lindblad R, Hu L, Oden NL, Wakim PG, Rosa CL, VanVeldhuisen PC. Mortality rates among substance use disorder participants in clinical trials: Pooled analysis of twenty-two clinical trials within the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment 2016;70:73-80.
-
Implementation of motivational interviewing in substance use disorder treatment: Research network participation and organizational compatibility.
Rieckmann TR, Abraham AJ, Bride BE. Implementation of motivational interviewing in substance use disorder treatment: Research network participation and organizational compatibility. Journal of Addiction Medicine 2016;10(6):402-407
-
The coupling of nicotine and stimulant craving during treatment for stimulant dependence.
Magee JC, Winhusen TJ. The coupling of nicotine and stimulant craving during treatment for stimulant dependence. Journal of Consulting and Clinical Psychology 2016;84(3):230-237.
-
Barriers and facilitators to tobacco cessation in a nationwide sample of addiction treatment programs.
Pagano A, Tajima BM, Guydish JR Barriers and facilitators to tobacco cessation in a nationwide sample of addiction treatment programs. Journal of Substance Abuse Treatment 2016;67:22-29.
-
Smoking among patients in substance use disorders treatment: Associations with tobacco advertising, anti-tobacco messages, and perceived health risks.
Campbell BK, Le T, Andrews KB, Pramod S, Guydish JR. Smoking among patients in substance use disorders treatment: Associations with tobacco advertising, anti-tobacco messages, and perceived health risks. American Journal of Drug and Alcohol Abuse 2016;42(6):649-656.